ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

This study is collecting blood samples over time from lung cancer patients who are taking targeted therapy drugs (called tyrosine kinase inhibitors or TKIs). The goal is to understand how cancer changes during treatment by analyzing genetic material found in the blood. **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic non-small cell lung cancer (NSCLC) with a specific genetic change (an oncogenic driver mutation) - You are currently being treated with a targeted therapy drug (TKI) as your standard care - You can understand and sign an informed consent form **You may NOT be eligible if...** - You cannot have blood drawn for study purposes Talk to your doctor to see if this trial is right for you.